Alkermes (ALKS) Competitors

Biogen (NASDAQ:BIIB) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.

Which has more risk & volatility, BIIB or ALKS?

Biogen has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in BIIB or ALKS?

87.9% of Biogen shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 4.9% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is BIIB or ALKS more profitable?

Alkermes has a net margin of 23.57% compared to Biogen's net margin of 16.87%. Alkermes' return on equity of 30.80% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Alkermes	23.57%	30.80%	19.09%

Does the MarketBeat Community believe in BIIB or ALKS?

Biogen received 1114 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 71.41% of users gave Biogen an outperform vote while only 70.41% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1816 71.41%	Underperform Votes 727 28.59%
Alkermes	Outperform Votes 702 70.41%	Underperform Votes 295 29.59%

Do analysts rate BIIB or ALKS?

Biogen presently has a consensus price target of $213.15, indicating a potential upside of 81.26%. Alkermes has a consensus price target of $38.50, indicating a potential upside of 39.19%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	18 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42
Alkermes	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has higher earnings and valuation, BIIB or ALKS?

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.78	$1.63B	$11.19	10.51
Alkermes	$1.56B	2.93	$367.07M	$2.17	12.75

Does the media prefer BIIB or ALKS?

In the previous week, Biogen had 18 more articles in the media than Alkermes. MarketBeat recorded 39 mentions for Biogen and 21 mentions for Alkermes. Alkermes' average media sentiment score of 1.04 beat Biogen's score of 1.00 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alkermes beats Biogen on 10 of the 18 factors compared between the two stocks.